Precigen
A biotech company focused on gene and cell therapies.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Precigen is a biotech company developing gene and cell therapies for oncology, infectious diseases, and rare diseases.
Products and positioning
Recent events
Precigen announces CFO appointment[1]
Reported:
Precigen announced Harry Thomasian Jr. as its chief financial officer, with the appointment set to take effect on October 18, 2021.
FDA clears Precigen's UltraPorator manufacturing device[2]
Reported:
Precigen announced that the US Food and Drug Administration cleared UltraPorator as a manufacturing device for its UltraCAR-T manufacturing process.
Precigen reports first-quarter 2020 results[3]
Reported:
Precigen announced first-quarter 2020 financial results, reporting revenue of $29.8 million and a net loss from continuing operations attributable to Precigen of $29.9 million.
FDA clears Precigen's PRGN-2009 investigational application[3]
Reported:
Precigen reported that the U.S. FDA cleared the Investigational New Drug application for PRGN-2009 to initiate a Phase 1/2 trial in HPV-positive solid tumors.
MBP Titan completes workforce reduction[3]
Reported:
Precigen reported that its wholly owned subsidiary MBP Titan significantly reduced its resource requirements through a workforce reduction, as the company focused resources on healthcare programs.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/precigen · Editorial policy · How profiles are compiled